Cargando…
Potassium management with finerenone: Practical aspects
INTRODUCTION: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes. METHODS: Two large, randomized trials have evaluated the eff...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659654/ https://www.ncbi.nlm.nih.gov/pubmed/36574588 http://dx.doi.org/10.1002/edm2.360 |
_version_ | 1784830248427192320 |
---|---|
author | Wanner, Christoph Fioretto, Paola Kovesdy, Csaba P. Malyszko, Jolanta Pecoits‐Filho, Roberto Schnell, Oliver Rossignol, Patrick |
author_facet | Wanner, Christoph Fioretto, Paola Kovesdy, Csaba P. Malyszko, Jolanta Pecoits‐Filho, Roberto Schnell, Oliver Rossignol, Patrick |
author_sort | Wanner, Christoph |
collection | PubMed |
description | INTRODUCTION: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes. METHODS: Two large, randomized trials have evaluated the effects of finerenone on clinical outcomes. The first trial (FIDELIO‐DKD) investigated renal outcomes, and the second (FIGARO‐DKD) cardiovascular outcomes. RESULTS: Patients in the two studies had a high intrinsic risk of hyperkalemia due to type 2 diabetes, treatment with optimized doses of an inhibitor of the renin‐angiotensin system, and, in some patients, their advanced chronic kidney disease. This was reflected in the incidence of hyperkalemia in the placebo group during the trials. Patients on finerenone had a significantly higher incidence of hyperkalemia compared with patients on placebo, but treatment discontinuation due to hyperkalemia was low, and no patients experienced death attributable to hyperkalemia. Structured routine potassium monitoring with temporary treatment interruption and dose reduction, as used in the two trials, should ensure the safe use of finerenone to protect the kidneys and cardiovascular system of patients with albuminuric chronic kidney disease and type 2 diabetes. CONCLUSIONS: The aim of this document is to highlight the routine potassium management required when using finerenone and to provide practical recommendations. |
format | Online Article Text |
id | pubmed-9659654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96596542022-11-14 Potassium management with finerenone: Practical aspects Wanner, Christoph Fioretto, Paola Kovesdy, Csaba P. Malyszko, Jolanta Pecoits‐Filho, Roberto Schnell, Oliver Rossignol, Patrick Endocrinol Diabetes Metab Research Article INTRODUCTION: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney disease with increased albuminuria and type 2 diabetes. METHODS: Two large, randomized trials have evaluated the effects of finerenone on clinical outcomes. The first trial (FIDELIO‐DKD) investigated renal outcomes, and the second (FIGARO‐DKD) cardiovascular outcomes. RESULTS: Patients in the two studies had a high intrinsic risk of hyperkalemia due to type 2 diabetes, treatment with optimized doses of an inhibitor of the renin‐angiotensin system, and, in some patients, their advanced chronic kidney disease. This was reflected in the incidence of hyperkalemia in the placebo group during the trials. Patients on finerenone had a significantly higher incidence of hyperkalemia compared with patients on placebo, but treatment discontinuation due to hyperkalemia was low, and no patients experienced death attributable to hyperkalemia. Structured routine potassium monitoring with temporary treatment interruption and dose reduction, as used in the two trials, should ensure the safe use of finerenone to protect the kidneys and cardiovascular system of patients with albuminuric chronic kidney disease and type 2 diabetes. CONCLUSIONS: The aim of this document is to highlight the routine potassium management required when using finerenone and to provide practical recommendations. John Wiley and Sons Inc. 2022-09-15 /pmc/articles/PMC9659654/ /pubmed/36574588 http://dx.doi.org/10.1002/edm2.360 Text en © 2022 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Wanner, Christoph Fioretto, Paola Kovesdy, Csaba P. Malyszko, Jolanta Pecoits‐Filho, Roberto Schnell, Oliver Rossignol, Patrick Potassium management with finerenone: Practical aspects |
title | Potassium management with finerenone: Practical aspects |
title_full | Potassium management with finerenone: Practical aspects |
title_fullStr | Potassium management with finerenone: Practical aspects |
title_full_unstemmed | Potassium management with finerenone: Practical aspects |
title_short | Potassium management with finerenone: Practical aspects |
title_sort | potassium management with finerenone: practical aspects |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659654/ https://www.ncbi.nlm.nih.gov/pubmed/36574588 http://dx.doi.org/10.1002/edm2.360 |
work_keys_str_mv | AT wannerchristoph potassiummanagementwithfinerenonepracticalaspects AT fiorettopaola potassiummanagementwithfinerenonepracticalaspects AT kovesdycsabap potassiummanagementwithfinerenonepracticalaspects AT malyszkojolanta potassiummanagementwithfinerenonepracticalaspects AT pecoitsfilhoroberto potassiummanagementwithfinerenonepracticalaspects AT schnelloliver potassiummanagementwithfinerenonepracticalaspects AT rossignolpatrick potassiummanagementwithfinerenonepracticalaspects |